Stocks to Watch: Penguin Solutions, Esperion Therapeutics

Dow Jones

10/08

By Kelly Cloonan

Penguin Solutions expects sales growth to slow in the current fiscal year after it swung to a profit in its latest quarter. The artificial intelligence company forecast sales growth of about 6%, plus or minus 10%, for fiscal 2026, compared to 17% growth in the year that ended Aug. 29. Chief Executive Mark Adams said the company is seeing momentum in its core businesses. Shares fell 13% to $23.60 in after-hours trading.

Esperion Therapeutics commenced an underwritten public offering of its common stock. All shares in the proposed offering will be sold by Esperion. In April, the biopharmaceutical company filed for a $400 million mixed shelf offering with the Securities and Exchange Commission. Shares slid 18% to $2.54 after market close.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

October 07, 2025 19:04 ET (23:04 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2573994973"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573994973\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573994973?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 07:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573994973","market":"fut","top_or_hot":-1,"title":"Stocks to Watch: Penguin Solutions, Esperion Therapeutics","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Penguin Solutions expects sales growth to slow in the current fiscal year after it swung to a profit in its latest quarter. The artificial intelligence company forecast sales growth of about 6%, plus or minus 10%, for fiscal 2026, compared to 17% growth in the year that ended Aug. 29. Chief Executive Mark Adams said the company is seeing momentum in its core businesses. Shares fell 13% to $23.60 in after-hours trading. \n</p>\n<p>\n  Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> commenced an underwritten public offering of its common stock. All shares in the proposed offering will be sold by Esperion. In April, the biopharmaceutical company filed for a $400 million mixed shelf offering with the Securities and Exchange Commission. Shares slid 18% to $2.54 after market close. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n   Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 07, 2025 19:04 ET (23:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: Penguin Solutions, Esperion Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: Penguin Solutions, Esperion Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-08 07:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Penguin Solutions expects sales growth to slow in the current fiscal year after it swung to a profit in its latest quarter. The artificial intelligence company forecast sales growth of about 6%, plus or minus 10%, for fiscal 2026, compared to 17% growth in the year that ended Aug. 29. Chief Executive Mark Adams said the company is seeing momentum in its core businesses. Shares fell 13% to $23.60 in after-hours trading. \n</p>\n<p>\n  Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> commenced an underwritten public offering of its common stock. All shares in the proposed offering will be sold by Esperion. In April, the biopharmaceutical company filed for a $400 million mixed shelf offering with the Securities and Exchange Commission. Shares slid 18% to $2.54 after market close. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n   Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 07, 2025 19:04 ET (23:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2573994973","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573994973","pubTimestamp":1759878240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Penguin Solutions expects sales growth to slow in the current fiscal year after it swung to a profit in its latest quarter. The artificial intelligence company forecast sales growth of about 6%, plus or minus 10%, for fiscal 2026, compared to 17% growth in the year that ended Aug. 29. Chief Executive Mark Adams said the company is seeing momentum in its core businesses. Shares fell 13% to $23.60 in after-hours trading.Esperion Therapeutics commenced an underwritten public offering of its common stock. All shares in the proposed offering will be sold by Esperion. In April, the biopharmaceutical company filed for a $400 million mixed shelf offering with the Securities and Exchange Commission. Shares slid 18% to $2.54 after market close.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ESPR":"Esperion Therapeutics Inc."},"translate_title":"值得关注的股票：Penguin Solutions、Esperion Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESPR":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Penguin Solutions expects sales growth to slow in the current fiscal year after it swung to a profit in its latest quarter. The artificial intelligence company forecast sales growth of about 6%, plus or minus 10%, for fiscal 2026, compared to 17% growth in the year that ended Aug. 29. Chief Executive Mark Adams said the company is seeing momentum in its core businesses. Shares fell 13% to $23.60 in after-hours trading. \n\n\n  Esperion Therapeutics commenced an underwritten public offering of its common stock. All shares in the proposed offering will be sold by Esperion. In April, the biopharmaceutical company filed for a $400 million mixed shelf offering with the Securities and Exchange Commission. Shares slid 18% to $2.54 after market close. \n\n\n \n\n\n   Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n  (END) Dow Jones Newswires\n\n\n  October 07, 2025 19:04 ET (23:04 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}